Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Novan to Report Full Year 2022 Financial Results on March 30, 2023
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q4 2021 Results - Earnings Call Transcript
Novan to Report Full Year 2021 Financial Results on February 22, 2022
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Novan Announces Strategic Priorities and Outlines Key Milestones
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q2 2021 Results - Earnings Call Transcript
Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Novan Stock Increases Over 10%: Why It Happened
Novan Announces Inclusion in Russell Microcap® Index
Novan Announces Closing of $40 Million Public Offering of Common Stock
Novan Stock Falls After Raising $40M Via Equity At 21% Discount
NOVN Stock Price Falls Over 10% Pre-Market: Why It Happened
Novan Announces Proposed Public Offering of Common Stock
NOVN Stock Price Increases Over 5% Pre-Market: Why It Happened
NOVN Stock Price: 62.39% Increase Explanation
4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now
NOVN Stock: The Positive Trial Results Sending Novan Skyrocketing Today
A Technical Look At Novan's Stock Amid 80% Spike
NOVN Stock Price: Over 30% Increase Pre-Market Explanation
Novan's Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
Results from Novan's Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
NOVN Stock: 1-For-10 Reverse Split
Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech
NOVN Stock Price Increased Over 10% Pre-Market: Why It Happened
Novan to Present at the H.C. Wainwright Global Life Sciences Conference
NOVN Stock Price Increased Over 28% Intraday: Why It Happened